There are 2789 resources available
736P - Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer (ANNIE): A multicenter, single-arm, phase II trial
Presenter: jihong Liu
Session: ePoster Display
737P - Phase II study of IV vinorelbine in relapsed platinum resistant or refractory C5 high grade serous primary peritoneal, fallopian tube or ovarian cancer (VIP)
Presenter: Natalie Ngoi
Session: ePoster Display
738P - Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial
Presenter: Maria-Pilar Barretina-Ginesta
Session: ePoster Display
739P - Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial
Presenter: Renaud Sabatier
Session: ePoster Display
740P - Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study
Presenter: Kristina Lindemann
Session: ePoster Display
741P - Immune features of high-grade ovarian cancer associated with exceptional disease free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study
Presenter: Louis Mourani
Session: ePoster Display
742P - Survival in patients (pts) with advanced ovarian cancer (AOC) changes with cumulative number of risk factors (RFs): A US real-world (RW) analysis
Presenter: Dana Chase
Session: ePoster Display
743P - Real-world outcomes in patients treated with trametinib for low grade serous ovarian carcinoma
Presenter: Rohan Shotton
Session: ePoster Display
744P - Use of PARPi among patients with advanced ovarian cancer: Results from a real-world database
Presenter: Shaheenah Dawood
Session: ePoster Display